156 related articles for article (PubMed ID: 200243)
21. Inhibitors of thromboxane synthase in human platelets.
Alusy UD; Hammarström S
FEBS Lett; 1977 Oct; 82(1):107-10. PubMed ID: 913565
[No Abstract] [Full Text] [Related]
22. Reorientation of prostaglandin endoperoxide metabolism by a thromboxane synthetase inhibitor: in vitro and clinical observations.
Vermylen J; Deckmyn H
Br J Clin Pharmacol; 1983; 15 Suppl 1(Suppl 1):17S-22S. PubMed ID: 6297527
[TBL] [Abstract][Full Text] [Related]
23. Endogenous prostacyclin contributes to the efficacy of a thromboxane synthetase inhibitor for preventing coronary artery thrombosis.
Aiken JW; Shebuski RJ; Miller OV; Gorman RR
J Pharmacol Exp Ther; 1981 Nov; 219(2):299-308. PubMed ID: 6270303
[No Abstract] [Full Text] [Related]
24. Modulation of human platelet function by prostacyclin and thromboxane A2.
Gorman RR
Fed Proc; 1979 Jan; 38(1):83-8. PubMed ID: 215465
[No Abstract] [Full Text] [Related]
25. Transient concentrations and agonist potency of PGH2 in platelet activation by endogenous arachidonate.
Hornberger W; Patscheke H
Eicosanoids; 1989; 2(4):241-8. PubMed ID: 2517034
[TBL] [Abstract][Full Text] [Related]
26. Prostaglandin endoperoxides and thromboxane A2 activate the same receptor isoforms in human platelets.
Vezza R; Mezzasoma AM; Venditti G; Gresele P
Thromb Haemost; 2002 Jan; 87(1):114-21. PubMed ID: 11848439
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of platelet aggregation by 1-alkylimidazole derivatives, thromboxane A synthetase inhibitors.
Kayama N; Sakaguchi K; Kaneko S; Kubota T; Fukuzawa T; Kawamura S; Yoshimoto T; Yamamoto S
Prostaglandins; 1981 Apr; 21(4):543-54. PubMed ID: 7196056
[TBL] [Abstract][Full Text] [Related]
28. SQ 22536, an adenylate-cyclase inhibitor, prevents the antiplatelet effect of dazoxiben, a thromboxane-synthetase inhibitor.
Bertelé V; Falanga A; Tomasiak M; Cerletti C; de Gaetano G
Thromb Haemost; 1984 Feb; 51(1):125-8. PubMed ID: 6326343
[TBL] [Abstract][Full Text] [Related]
29. Effects of 2-indolecarbohydrazides on thromboxane synthetase activity and on in vitro and ex vivo blood platelet aggregation. New selective inhibitors.
Monge A; Erro A; Parrado P; Font M; Aldana I; Rocha E; Fernandez-Alvarez E
Arzneimittelforschung; 1986 Aug; 36(8):1184-6. PubMed ID: 3096343
[TBL] [Abstract][Full Text] [Related]
30. Stereocontrolled synthesis of 7-oxabicyclo (2.2.1) heptane prostaglandin analogs as thromboxane A2 antagonists.
Sprague PW; Heikes JE; Harris DN; Greenberg R
Adv Prostaglandin Thromboxane Res; 1980; 6():493-6. PubMed ID: 7189952
[No Abstract] [Full Text] [Related]
31. Prostaglandin endoperoxides and thromboxane A2 can induce platelet aggregation in the absence of secretion.
Charo IF; Feinman RD; Detwiler TC; Smith JB; Ingerman CM; Silver MJ
Nature; 1977 Sep; 269(5623):66-9. PubMed ID: 895887
[No Abstract] [Full Text] [Related]
32. Analysis of the biological activity of azoprostanoids in human platelets.
Gorman RR; Shebuski RJ; Aiken JW; Bundy GL
Fed Proc; 1981 May; 40(7):1997-2000. PubMed ID: 7014259
[TBL] [Abstract][Full Text] [Related]
33. R 68 070: thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade, combined in one molecule.
De Clerck F; Beetens J; de Chaffoy de Courcelles D; Vercammen E; Freyne E; Janssen PA
Prog Clin Biol Res; 1989; 301():567-72. PubMed ID: 2529556
[No Abstract] [Full Text] [Related]
34. Kinetic studies on the conversion of prostaglandin endoperoxide PGH2 by thromboxane synthase.
Anderson MW; Crutchley DJ; Tainer BE; Eling TE
Prostaglandins; 1978 Oct; 16(4):563-70. PubMed ID: 725086
[TBL] [Abstract][Full Text] [Related]
35. Evidence for a bidirectional prostaglandin endoperoxide shunt between platelets and the bovine coronary artery.
Mayeux PR; Kadowitz PJ; McNamara DB
Biochim Biophys Acta; 1989 Mar; 1011(1):18-24. PubMed ID: 2493809
[TBL] [Abstract][Full Text] [Related]
36. [Suppression of platelet aggregation as a result of two-component inhibition of a polyenzyme system of thromboxane synthesis].
Varfolomeev SD; Lakin KM; Mevkh AT; Novikova NV; Rukazenkov IuZ
Dokl Akad Nauk SSSR; 1985; 282(1):194-6. PubMed ID: 3928305
[No Abstract] [Full Text] [Related]
37. Application of imidazole as a selective inhibitor thromboxane synthetase in human platelets.
Needleman P; Raz A; Ferrendelli JA; Minkes M
Proc Natl Acad Sci U S A; 1977 Apr; 74(4):1716-20. PubMed ID: 193113
[TBL] [Abstract][Full Text] [Related]
38. Prostaglandin endoperoxides promote calcium release from a platelet membrane fraction in vitro.
Gerrard JM; Butler AM; Graff G; Stoddard SF; White JG
Prostaglandins Med; 1978 Nov; 1(5):373-85. PubMed ID: 364508
[TBL] [Abstract][Full Text] [Related]
39. Effects of thromboxane antagonist EP 045 on platelet aggregation.
Jones RL; Wilson NH; Armstrong RA; Peesapati V; Smith GM
Adv Prostaglandin Thromboxane Leukot Res; 1983; 11():345-50. PubMed ID: 6303074
[No Abstract] [Full Text] [Related]
40. Renal vascular effects of endoperoxide analogs, prostaglandins, and arachidonic acid.
Feigen LP; Chapnick BM; Flemming JE; Flemming JM; Kadowitz PJ
Am J Physiol; 1977 Nov; 233(5):H573-9. PubMed ID: 920820
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
